Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)

Jean-Pascal Lefaucheur; Nathalie André-Obadia; Andrea Antal; Samar S Ayache; Chris Baeken; David H Benninger; Roberto M Cantello; Massimo Cincotta; Mamede de Carvalho; Dirk De Ridder; Hervé Devanne; Vincenzo Di Lazzaro; Saša R Filipović; Friedhelm C Hummel; Satu K Jääskeläinen; Vasilios K Kimiskidis; Giacomo Koch; Berthold Langguth; Thomas Nyffeler; Antonio Oliviero; Frank Padberg; Emmanuel Poulet; Simone Rossi; Paolo Maria Rossini; John C Rothwell; Carlos Schönfeldt-Lecuona; Hartwig R Siebner; Christina W Slotema; Charlotte J Stagg; Josep Valls-Sole; Ulf Ziemann; Walter Paulus; Luis Garcia-Larrea

doi:10.1016/j.clinph.2014.05.021

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)

Jean-Pascal Lefaucheur, Nathalie André-Obadia, Andrea Antal, Samar S Ayache, Chris Baeken, David H Benninger, Roberto M Cantello, Massimo Cincotta, Mamede de Carvalho, Dirk De Ridder, Hervé Devanne, Vincenzo Di Lazzaro, Saša R Filipović, Friedhelm C Hummel, Satu K Jääskeläinen, Vasilios K Kimiskidis, Giacomo Koch, Berthold Langguth, Thomas Nyffeler, Antonio OlivieroFrank Padberg, Emmanuel Poulet, Simone Rossi, Paolo Maria Rossini, John C Rothwell, Carlos Schönfeldt-Lecuona, Hartwig R Siebner, Christina W Slotema, Charlotte J Stagg, Josep Valls-Sole, Ulf Ziemann, Walter Paulus, Luis Garcia-Larrea

Institut for Klinisk Medicin

1047 Citationer (Scopus)

Abstract

A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.

Originalsprog	Engelsk
Tidsskrift	Clinical Neurophysiology
Vol/bind	125
Udgave nummer	11
Sider (fra-til)	2150–2206
Antal sider	56
ISSN	1388-2457
DOI	https://doi.org/10.1016/j.clinph.2014.05.021
Status	Udgivet - nov. 2014

Adgang til dokumentet

10.1016/j.clinph.2014.05.021

Citationsformater

Lefaucheur, J-P., André-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., Devanne, H., Di Lazzaro, V., Filipović, S. R., Hummel, F. C., Jääskeläinen, S. K., Kimiskidis, V. K., Koch, G., Langguth, B., Nyffeler, T., ... Garcia-Larrea, L. (2014). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology, 125(11), 2150–2206. https://doi.org/10.1016/j.clinph.2014.05.021

Lefaucheur, J-P, André-Obadia, N, Antal, A, Ayache, SS, Baeken, C, Benninger, DH, Cantello, RM, Cincotta, M, de Carvalho, M, De Ridder, D, Devanne, H, Di Lazzaro, V, Filipović, SR, Hummel, FC, Jääskeläinen, SK, Kimiskidis, VK, Koch, G, Langguth, B, Nyffeler, T, Oliviero, A, Padberg, F, Poulet, E, Rossi, S, Rossini, PM, Rothwell, JC, Schönfeldt-Lecuona, C, Siebner, HR, Slotema, CW, Stagg, CJ, Valls-Sole, J, Ziemann, U, Paulus, W & Garcia-Larrea, L 2014, 'Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)', Clinical Neurophysiology, bind 125, nr. 11, s. 2150–2206. https://doi.org/10.1016/j.clinph.2014.05.021

@article{74a9650cd9c34c4cb0def33f830d965a,

title = "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)",

abstract = "A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.",

author = "Jean-Pascal Lefaucheur and Nathalie Andr{\'e}-Obadia and Andrea Antal and Ayache, {Samar S} and Chris Baeken and Benninger, {David H} and Cantello, {Roberto M} and Massimo Cincotta and {de Carvalho}, Mamede and {De Ridder}, Dirk and Herv{\'e} Devanne and {Di Lazzaro}, Vincenzo and Filipovi{\'c}, {Sa{\v s}a R} and Hummel, {Friedhelm C} and J{\"a}{\"a}skel{\"a}inen, {Satu K} and Kimiskidis, {Vasilios K} and Giacomo Koch and Berthold Langguth and Thomas Nyffeler and Antonio Oliviero and Frank Padberg and Emmanuel Poulet and Simone Rossi and Rossini, {Paolo Maria} and Rothwell, {John C} and Carlos Sch{\"o}nfeldt-Lecuona and Siebner, {Hartwig R} and Slotema, {Christina W} and Stagg, {Charlotte J} and Josep Valls-Sole and Ulf Ziemann and Walter Paulus and Luis Garcia-Larrea",

year = "2014",

month = nov,

doi = "10.1016/j.clinph.2014.05.021",

language = "English",

volume = "125",

pages = "2150–2206",

journal = "Clinical Neurophysiology",

issn = "1388-2457",

publisher = "Elsevier Ireland Ltd",

number = "11",

}

TY - JOUR

T1 - Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)

AU - Lefaucheur, Jean-Pascal

AU - André-Obadia, Nathalie

AU - Antal, Andrea

AU - Ayache, Samar S

AU - Baeken, Chris

AU - Benninger, David H

AU - Cantello, Roberto M

AU - Cincotta, Massimo

AU - de Carvalho, Mamede

AU - De Ridder, Dirk

AU - Devanne, Hervé

AU - Di Lazzaro, Vincenzo

AU - Filipović, Saša R

AU - Hummel, Friedhelm C

AU - Jääskeläinen, Satu K

AU - Kimiskidis, Vasilios K

AU - Koch, Giacomo

AU - Langguth, Berthold

AU - Nyffeler, Thomas

AU - Oliviero, Antonio

AU - Padberg, Frank

AU - Poulet, Emmanuel

AU - Rossi, Simone

AU - Rossini, Paolo Maria

AU - Rothwell, John C

AU - Schönfeldt-Lecuona, Carlos

AU - Siebner, Hartwig R

AU - Slotema, Christina W

AU - Stagg, Charlotte J

AU - Valls-Sole, Josep

AU - Ziemann, Ulf

AU - Paulus, Walter

AU - Garcia-Larrea, Luis

PY - 2014/11

Y1 - 2014/11

N2 - A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.

AB - A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.

U2 - 10.1016/j.clinph.2014.05.021

DO - 10.1016/j.clinph.2014.05.021

M3 - Journal article

C2 - 25034472

SN - 1388-2457

VL - 125

SP - 2150

EP - 2206

JO - Clinical Neurophysiology

JF - Clinical Neurophysiology

IS - 11

ER -

Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater